Impel Pharmaceuticals (IMPL) Institutional Ownership → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free IMPL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share OwnershipStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaStock AnalysisEarningsHeadlinesInsider TradesOwnershipShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Impel Pharmaceuticals (NASDAQ:IMPL)CurrentInstitutional OwnershipPercentage73.88%Number ofInstitutional Buyers(last 12 months)1TotalInstitutional Inflows(last 12 months)$10.80KNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$179.48K Get IMPL Insider Trade Alerts Want to know when executives and insiders are buying or selling Impel Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data IMPL Institutional Buying and Selling by Quarter Ad Crypto 101 MediaIncredible Opportunity to Retire FAST!A brand-new guide from the host of one of the world's largest cryptocurrency podcasts lays out an action plan that could help you retire quickly and comfortably in today's crypto market.Click here to get instant access to the guide Impel Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/15/2023Lasry Marc225,874$97K0.1%-44.7%0.951% 8/9/2023DCF Advisers LLC303,605$386K0.2%-20.8%1.278% 7/17/2023Mcdonald Partners LLC20,200$26K0.0%+72.6%0.085% 1/18/2023Mcdonald Partners LLC11,700$44K0.0%N/A0.049% 11/14/2022Ergoteles LLC24,447$119K0.0%-13.9%0.103% 8/15/2022Opaleye Management Inc.144,642$1.35M0.6%N/A0.624% Get the Latest News and Ratings for IMPL and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 8/15/2022Laurion Capital Management LP124,800$1.16M0.0%N/A0.539% 8/11/2022DCF Advisers LLC438,566$4.09M2.4%+19.5%1.893% 5/9/2022Qube Research & Technologies Ltd11,867$76K0.0%-41.7%0.051% 2/14/2022Point72 Hong Kong Ltd5,864$51K0.0%N/A0.025% 2/14/2022Point72 Asset Management L.P.208,760$1.80M0.0%N/A0.906% 2/10/2022Qube Research & Technologies Ltd20,342$176K0.0%N/A0.088% 2/9/2022Alps Advisors Inc.26,662$230K0.0%N/A0.116% 2/3/2022Brighton Jones LLC14,145$122K0.0%N/A0.061% 2/1/2022Qube Research & Technologies Ltd20,342$176K0.0%N/A0.088% 1/28/2022Allspring Global Investments Holdings LLC26,675$230K0.0%N/A0.116% 1/25/2022Epiq Partners LLC18,646$161K0.1%N/A0.081% 12/10/2021Towercrest Capital Management50,500$615K0.1%N/A0.219% 11/15/2021First Manhattan Co.6,700$81K0.0%N/A0.034% 11/12/2021Geode Capital Management LLC117,916$1.44M0.0%+131.5%0.604% 11/9/2021BlackRock Inc.268,730$3.27M0.0%+7.0%1.377% 11/8/2021Trustcore Financial Services LLC13,407$163K0.0%N/A0.069% 11/8/2021Russell Investments Group Ltd.200,806$2.45M0.0%N/A1.029% 11/2/2021New York State Common Retirement Fund6,867$84K0.0%-49.9%0.035% 11/2/2021Victory Capital Management Inc.80,390$979K0.0%-28.7%0.412% 10/13/2021FNY Investment Advisers LLC5,377$65K0.0%N/A0.028% 8/17/2021Woodline Partners LP119,615$1.06M0.0%N/A0.537% 8/17/2021Zimmer Partners LP25,000$221K0.0%N/A0.112% 8/17/2021Kohlberg Kravis Roberts & Co. L.P.3,802,639$33.65M0.1%N/A17.071% 8/16/20215AM Venture Management LLC2,884,791$25.53M6.4%N/A12.950% 8/16/2021California State Teachers Retirement System7,464$66K0.0%N/A0.034% 8/16/2021venBio Partners LLC2,759,791$24.42M2.9%N/A12.389% 8/16/2021Pinz Capital Management LP6,188$55K0.0%N/A0.028% 8/16/2021Charles Schwab Investment Management Inc.11,413$102K0.0%N/A0.051% 8/16/2021State Street Corp46,298$410K0.0%N/A0.208% 8/13/2021Northern Trust Corp58,493$518K0.0%N/A0.263% 8/13/2021Geode Capital Management LLC50,942$450K0.0%N/A0.229% 8/13/2021Vanguard Group Inc.183,753$1.63M0.0%N/A0.825% 8/12/2021JPMorgan Chase & Co.6,653$59K0.0%N/A0.030% 8/11/2021BlackRock Inc.251,063$2.22M0.0%N/A1.127% Global crypto currency reset (41 major banks signed up) (Ad)Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project... Here's everything you need to know.8/11/2021Deutsche Bank AG3,196$28K0.0%N/A0.014% 8/10/2021Norwest Venture Partners Xiv LP3,077,198$27.23M31.4%N/A13.814% 8/3/2021Victory Capital Management Inc.112,730$998K0.0%N/A0.506% (Data available from 1/1/2016 forward) IMPL Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IMPL shares? During the previous two years, the following institutional investors and hedge funds held shares of Impel Pharmaceuticals shares: Opaleye Management Inc. ($1.35M), Laurion Capital Management LP ($1.16M), DCF Advisers LLC ($386K), Ergoteles LLC ($119K), Lasry Marc ($97K), and Qube Research & Technologies Ltd ($76K), and Mcdonald Partners LLC ($26K).Learn more on IMPL's institutional investors. What percentage of Impel Pharmaceuticals stock is owned by institutional investors? 73.88% of Impel Pharmaceuticals stock is owned by institutional investors. Learn more on IMPL's institutional investor holdings. Which institutional investors have been buying Impel Pharmaceuticals stock? The following institutional investors have purchased Impel Pharmaceuticals stock in the last 24 months: Opaleye Management Inc. ($144.64K), Laurion Capital Management LP ($124.80K), DCF Advisers LLC ($71.51K), and Mcdonald Partners LLC ($20.20K). How much institutional buying is happening at Impel Pharmaceuticals? Institutional investors have bought a total of 361,150 shares in the last 24 months. This purchase volume represents approximately $3.23M in transactions. Which Impel Pharmaceuticals major shareholders have been selling company stock? The following institutional investors have sold Impel Pharmaceuticals stock in the last 24 months: Lasry Marc ($182.46K), DCF Advisers LLC ($79.54K), Qube Research & Technologies Ltd ($8.48K), and Ergoteles LLC ($3.95K). How much institutional selling is happening at Impel Pharmaceuticals? Institutional investors have sold a total of 274,426 shares in the last 24 months. This volume of shares sold represents approximately $252.71K in transactions. Related Companies: NEPT Institutional Ownership EVLO Institutional Ownership BXRX Institutional Ownership BLPH Institutional Ownership ATNF Institutional Ownership ADTX Institutional Ownership ALLR Institutional Ownership PRFX Institutional Ownership NBSE Institutional Ownership APVO Institutional Ownership This page (NASDAQ:IMPL) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersPentagon contract could send this $2 AI stock soaringBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Impel Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.